Alik Farber, MD
James Utley Professor and Chair of Surgery
Boston University Chobanian & Avedisian School of Medicine

MD, Harvard Medical School
MBA, Brandeis University
BS, Brown University



Alik Farber, MD, MBA, is interim Chair of the Departments of Surgery and Radiology at the Boston University Chobanian & Avedisian School of Medicine. Dr. Farber is also interim Chief of the Department of Surgery at Boston Medical Center, where he is Associate Chief Medical Officer for Surgical Services and Chief of the Division of Vascular & Endovascular Surgery.

After earning his undergraduate degree from Brown University, Dr. Farber received his medical degree from Harvard Medical School. He completed residency in general surgery at Massachusetts General Hospital, a vascular surgery fellowship at Dartmouth-Hitchcock Medical Center, and an endovascular surgery fellowship at Southern Illinois School of Medicine. He received an MBA from the Heller School for Social Policy and Management at Brandeis University.

Dr. Farber began his career in 1999 as a vascular surgeon in private practice at Cedars-Sinai Medical Center in Los Angeles. In 2005, he was recruited to Boston Medical Center as an attending vascular surgeon and joined the faculty of the Chobanian & Avedisian School of Medicine as an Assistant Professor, rising to full Professor in 2015. Throughout his tenure, Dr. Farber has been involved in diverse academic, clinical operational, and leadership roles.

Dr. Farber’s clinical practice focuses on peripheral artery disease. An internationally recognized authority on limb ischemia, he has been invited to contribute to multidisciplinary consensus statements and has lectured across the world on this topic. Dr. Farber has served as principal investigator (PI) for multiple clinical trials involving wound care, intermittent claudication, and deep-vein arterialization. Most recently he served as co-PI of the landmark Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial. Funded by the National Heart, Lung, and Blood Institute, this international, multicenter, randomized controlled trial compared traditional bypass surgery with endovascular treatment for patients with chronic limb threatening ischemia. More than 1,800 patients at 150 sites across North America, Europe, and New Zealand were enrolled, with results published in The New England Journal of Medicine in 2022. Dr. Farber, who chairs the BEST-CLI Publications Committee, continues to be actively involved in trial dataset analysis and research dissemination through the BEST-CLI Collaborative, funded by the Novo Nordisk Foundation.

A fellow of the American College of Surgeons and a distinguished fellow of the Society of Vascular Surgery, Dr. Farber frequently serves in leadership roles for professional organizations. Currently, he is Secretary of the Society for Clinical Vascular Surgery and Treasurer of both the New England Society for Vascular Surgery and the Massachusetts Chapter of the American College of Surgeons.

Dr. Farber has authored more than 260 peer-reviewed manuscripts and 30 book chapters, and has edited two textbooks. He has given more than 160 presentations in over 20 countries.

Surgeon-in-Chief
Boston Medical Center


Professor
Boston University Chobanian & Avedisian School of Medicine
Surgery
Vascular and Endovascular Surgery

Associate Chief Medical Officer for Surgical Services
Boston Medical Center


Professor
Boston University Chobanian & Avedisian School of Medicine
Radiology
Vascular & Interventional

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols
05/01/2012 - 12/31/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm^2 to <= 36 cm^2
10/15/2013 - 08/30/2015 (PI)
HealthPoint Limited


A Non-Interventional Safety Study Providing 12 Months Follow-Up from First Exposure to HP802-247 in Subjects with Venous Leg Ulcer
05/01/2012 - 04/30/2015 (PI)
HealthPoint Limited


Observational Study of Tissue Plasminogen Activator Used for Catheter Directed Thrombolysis in Patients with Acute Lower Extremety Native Artery or Bypass Graft Occlusion
01/27/2014 - 01/26/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
05/01/2012 - 04/30/2014 (PI)
HealthPoint Limited


Vital Access Venous Window Needle Guide for salvage of AV Fistulae (SAVE) Trial
08/15/2012 - 08/14/2013 (PI)
Vital Access Corp


IN-BALANCE VLU (Inflammation, Bacteria, and Angiogenesis effects in launching venous leg ulcer healing: a clinical evaluation)
08/01/2012 - 07/31/2013 (PI)
Celleration, Inc.


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers
08/01/2009 - 12/31/2011 (PI)
HealthPoint Limited


Showing 10 of 16 results. Show All Results

Peripheral Bypass Trial for Completion Control
11/08/2024 - 11/07/2027 (PI)
Medistim ASA

Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and with Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
10/12/2022 - 10/12/2025 (PI)
Acera Surgical Inc.


Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (Best-CLI)
09/01/2022 - 08/31/2025 (Subcontract PI)
PI: Alik Farber, MD
Brigham and Womens Hospital Novo Nordisk Fdn


A multi-center prospective study to evaluate the safety and effectiveness of the VasQ external suppo
11/01/2017 - 01/31/2025 (PI)
Laminate Medical Technologies Inc.


LF-CA-PR-53-PROMISE III Trial
12/09/2022 - 10/31/2024 (PI)
LimFlow Inc


A Pivotal Study to Investigate the Safety and Effectiveness of the Limflow System for the…
12/11/2019 - 10/31/2024 (PI)
LimFlow Inc


Novonordisk-NN9535-4533
09/14/2021 - 09/14/2024 (PI)
Novo Nordisk


A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dressing on subjects with lower extremity venous ulcerss
10/14/2020 - 10/14/2023 (PI)
Medline Industries LLC


Natural Progression of High-Risk Chronic Limb-Threatening Ischemia. The CLariTI Study.
03/25/2021 - 08/31/2023 (PI)
LimFlow Inc


A multicenter, prospective, randomized, placebo controlled, double blind study performed to…
09/24/2019 - 08/31/2023 (PI)
MediWound Ltd.


Showing 10 of 20 results. Show All Results

Title

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Malas MB, Hamouda M, Farber A. Reply. J Vasc Surg. 2025 Jun; 81(6):1531-1532. PMID: 40414650
     
  2. Siracuse JJ, Kaufman JA, Farber A, Menard MT, Rosenfield K, Conte MS, Schanzer A, Powell RJ, Venermo M, Doros G, Faries P, Strong MB, Dake MD. Antiproliferative endovascular drug technology is associated with fewer major reinterventions after femoropopliteal interventions for chronic limb-threatening ischemia. J Vasc Surg. 2025 May 29.View Related Profiles. PMID: 40464723
     
  3. Sullivan AE, Huang S, Kundu S, Thomas VE, Clair DG, Aday AW, Menard MT, Farber A, Rosenfield K, Newman JD, Berger JS, Wells QS, Freiberg MS, Linton MF, Beckman JA. Association of Lipoprotein(a) With Major Adverse Limb Events and All-Cause Mortality Following Revascularization for Chronic Limb-Threatening Ischemia: A Substudy of the BEST-CLI Trial. J Am Heart Assoc. 2025 Jun 03; 14(11):e041177. PMID: 40401600
     
  4. Lucas JF, Secemsky E, Song Y, Hussain MA, Hentschel D, Woodside KJ, Ozaki CK, Farber A, Dillavou E. Comparative effectiveness of arteriovenous fistulas created with a nitinol extravascular support in patients with advanced kidney disease. J Vasc Access. 2025 May 03; 11297298251326967. PMID: 40317219
     
  5. Kashyap VS, Beckman JA, Doros G, Menard MT, Rosenfield K, Creager MA, Tuttle KR, McGinigle KL, Huber T, Kinlay S, Drooz AT, Strong MB, Weinberg I, Farber A, Jaff MR. Optimal Medical Therapy Is Associated With Improved Limb Outcomes in PAD Patients: A BEST-CLI Substudy. J Am Coll Cardiol. 2025 Apr 22; 85(15):1568-1572.View Related Profiles. PMID: 40240095
     
  6. Cheng TW, Farber A, Alonso A, King EG, Columbo JA, Hicks CW, Patel VI, Garg K, Stangenberg L, Siracuse JJ. Anticoagulation does not improve limb outcomes after lower extremity cryopreserved vein bypass. J Vasc Surg. 2025 Apr 08.View Related Profiles. PMID: 40209865
     
  7. Farber A, Menard MT, Conte MS, Rosenfield K, Hicks CW, Doros G, Strong MB, Houlind K, Kolh P, Siracuse JJ. Bypass After Failed Endovascular Intervention Is Associated with an Increased Risk of Above Ankle Amputation Among Patients with Chronic Limb Threatening Ischaemia in a Randomised Trial Population. Eur J Vasc Endovasc Surg. 2025 Apr 04.View Related Profiles. PMID: 40188865
     
  8. Shah KB, Aridi H, Dake MD, Doros G, Farber A, Menard MT, Motaganahalli R, Ochoa Chaar C, Rosenfield K, Scali ST, Shah SK, Strong MB, Upchurch GR, Robinson WP. Age-Related Outcomes After Revascularization for Chronic Limb-Threatening Ischemia: An Analysis of BEST-CLI. Circ Cardiovasc Interv. 2025 Jun; 18(6):e014833.View Related Profiles. PMID: 40177778
     
  9. Zywicka EM, Moore AJ, Twine C, Behrendt CA, Bosiers M, Brodmann M, Choke E, deBorst GJ, Diamantopoulos A, Enzmann F, Farber A, Ansel G, Gattuso D, Goh GS, Yann G, Jansen S, Landini M, Lejay A, Lichtenberg M, Menard M, Mezes P, Mills J, Nixon J, Nordanstig J, O'Connell K, Ozdemir B, Patrone L, Puppala S, Saratzis A, Secemsky EA, Sigrid N, Stavroulakis K, Steiner S, Teraa M, Van Herzeele I, Venermo M, Zeller T, Mouton R, Hinchliffe RJ. Endovascular treatment of peripheral arterial disease: Endo-STAR framework for the design, conduct, and reporting of trials. Br J Surg. 2025 Mar 28; 112(4). PMID: 40241414; PMCID: PMC12003854; DOI: 10.1093/bjs/znaf020;
     
  10. Ramkumar N, Goodney PP, Moore K, Goodney AJ, Ponukumati AS, Menard M, Farber A, Staiger D. Selecting Treatments for Peripheral Artery Disease: Differences Between Registry and a Randomized Controlled Trial Population. J Surg Res. 2025 Apr; 308:286-294. PMID: 40138771
     
Showing 10 of 389 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 388 publications over 27 distinct years, with a maximum of 41 publications in 2016

YearPublications
19921
19931
19992
20011
20022
20033
20044
20051
20073
20082
20096
20104
201112
20129
201319
201415
201521
201641
201738
201840
201925
202036
202119
202214
202323
202427
202519

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
Contact for Mentoring:

85 E. Concord St.
Boston MA 02118
Google Map


Farber's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_